What is CGEN stock price today?

CGEN (Compugen Ltd) stock is trading at $2.88 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is CGEN stock going up or down today?

CGEN stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy CGEN stock now?

The decision to buy CGEN depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is CGEN a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for CGEN based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is CGEN stock overvalued or undervalued?

CGEN currently trades at a P/E ratio of 7.42, which may suggest attractive valuation. Our DCF calculator provides intrinsic value estimates to help determine if CGEN is fairly priced.

What is CGEN's P/E ratio?

CGEN has a price-to-earnings (P/E) ratio of 7.42, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is CGEN's market cap?

CGEN (Compugen Ltd) has a market capitalization of $0.27 billion, making it a small-cap stock.

What is CGEN's price to book ratio?

CGEN trades at a price-to-book (P/B) ratio of 2.60, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does CGEN pay dividends?

CGEN does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is CGEN's dividend yield?

CGEN does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is CGEN stock a good long-term investment?

CGEN's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is CGEN's revenue growth rate?

CGEN has shown revenue growth of 44.8% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, CGEN is profitable with a profit margin of 0.5%. This indicates the company generates 0.5 cents of profit for every dollar of revenue.

What are the risks of investing in CGEN?

Key risks for CGEN include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does CGEN compare to its competitors?

Compare CGEN to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize CGEN's performance and positioning.

What is CGEN's stock price target for 2026?

Our AI model provides price targets for CGEN based on fundamental analysis: Bull case $3.74 (+30%), Base case $3.31 (+15%), Bear case $2.59 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about CGEN?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for CGEN. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is CGEN's next earnings report?

CGEN reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

CGEN - Compugen Ltd

NYSE * Health Care * Biotechnology

$2.88

+$0.06 (+2.13%)

About Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. The company was incorporated in 1993 and is headquartered in Holon, Israel.

CGEN Key Statistics

Market Cap

$267.82M

P/E Ratio

7.42

P/B Ratio

2.60

EPS

$0.38

Revenue Growth

+44.8%

Profit Margin

0.5%

Employees

How CGEN Compares to Peers

CGEN has the lowest P/E ratio in Biotechnology, suggesting it may be the most undervalued

CGEN has the highest profit margins in Biotechnology

CGEN has the fastest revenue growth among competitors

P/E Rank

of 6

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
CGEN(This stock)	$267.82M	7.4	45%	0.5%	-
AMGNAmgen Inc	$191.53B	24.9	0%	0.2%	vs AMGN
GILDGilead Sciences	$170.84B	20.3	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$112.22B	28.8	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.35B	18.1	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.91B	20.9	-0%	0.1%	vs BIIB

Compugen Ltd Company Information

Headquarters: Israel
Website: cgen.com
Sector: Health Care
Industry: Biotechnology

About Compugen Ltd

CGEN Key Statistics

How CGEN Compares to Peers

Compugen Ltd Company Information

Upcoming Events for CGEN